Novartis Sells Influenza Vaccine Unit To Australia’s CSL For $275 Million
This article was originally published in PharmAsia News
Executive Summary
Novartis sells its influenza vaccines unit to Australia’s CSL, creating the world’s No. 2 player in the segment.